News

RGX-314 eyed by investigators as a therapeutic option for exudative AMD.

An international research team has shown that optogenetic therapy has helped to partially regain visual function in a patient with retinitis pigmentosa. This is a milestone towards a gene therapy that could restore vision.

Preexisting neutralizing antibodies associated with the inflammatory changes.

Novel therapies are shifting the paradigm in care of retinal diseases

Investigators at Mount Sinai report that ocular cells may be infected directly by the virus, with the limbus especially susceptible.

Study results show that aflibercept-treated eyes are protected.

Study results show the device offers an effective long-term option for patients.

Prevent Blindness dedicates the third week of May to raising awareness of the benefit of genetic testing, variety of retinal diseases, and available resources.

Mark Pennesi, MD, PhD, reports during ARVO 2021 that preliminary results have shown that AGTC-401 and AGTC-402 seem safe and well tolerated in patients with ACHM.

In a presentation at ARVO, Friederike Kortuem, MD, MSc, explains that treatment with voretigene neparvovec-rzyl led to a short-term change in the foveal morphology in a patient with visual impairment that included nyctalopia and decreased visual acuity in early childhood.

Clinicians' knowledge of the epidemiology, natural history, causal mechanisms, and treatments for diabetic retinopathy (DR) has evolved dramatically over recent decades.

In a clinical trial, investigators used an adeno-associated viral vector to deliver a normal functioning copy of the RPGR gene via subretinal injection.

EYS809, a non-viral gene therapy sustained drug-delivery product that delivers anti-vascular endothelial growth factor to the eye, may replace the need for repeated intravitreal anti-VEGF injections and improve vision in patients diagnosed with wet age-related macular degeneration.

Logan Vander Woude, DO, MPH, examines research on improved resolution of symptomatic vitreomacular traction as an attempt to further refine the potential factors predictive of better outcomes.

Robyn Guymer, PhD, MBBS, highlights the latest trial results for faricimab, the first bispecific antibody designed for intraocular use in treating patients with neovascular age-related macular degeneration.

Sunil Srivastava, MD, examines why and how optical coherence tomography characteristics may be predictive of the efficacy of the injections.

Bryce Buchowicz, MD, outlines roadblocks to timely diagnosis of central retinal artery occlusion and treatment with tissue plasminogen activator during a virtual presentation at ARVO.

Logan Vander Woude, DO, MPH, takes a deeper dive into symptomatic vitreomacular traction research in an attempt to further refine the potential factors predictive of better outcomes.

Investigators offer insight on how patients with BRVO or CRVO with any lapse in treatment of 3 months or longer are at risk for poorer outcomes.

John Wells, MD, presents efficacy, durability, and safety findings from phase 3 YOSEMITE and RHINE trials during the virtual ARVO meeting.

Safety data on non-clinician-led services have shown a low complication rate

Let the countdown begin for May as ‘month of ARVO’ and Annual Meeting

Community support and research continue to boost treatment in children

Study evaluates the impact of surgical procedure on visual outcomes in patients

Easier, more accessible functional studies have been made possible

Insulin pumps, digital technology and outcome analyses are useful tools

Studies are uncovering a range of potential treatment options for disorders

Dexamethasone implant is key to treating non-infectious posterior segment uveitis